Harbor Capital Advisors Inc. Has $3.35 Million Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Harbor Capital Advisors Inc. grew its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 25.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 46,931 shares of the company's stock after buying an additional 9,635 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.10% of Soleno Therapeutics worth $3,353,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AlphaQuest LLC lifted its holdings in Soleno Therapeutics by 1,154.4% during the 4th quarter. AlphaQuest LLC now owns 715 shares of the company's stock worth $32,000 after buying an additional 658 shares in the last quarter. US Bancorp DE bought a new stake in shares of Soleno Therapeutics during the fourth quarter worth $34,000. Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of Soleno Therapeutics during the fourth quarter valued at $81,000. Summit Investment Advisors Inc. boosted its holdings in Soleno Therapeutics by 24.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock valued at $120,000 after acquiring an additional 522 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Soleno Therapeutics in the fourth quarter valued at about $193,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Soleno Therapeutics

In other news, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares of the company's stock, valued at approximately $39,021,879.12. This represents a 54.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Patricia C. Hirano sold 3,782 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total transaction of $265,156.02. Following the transaction, the insider now owns 27,036 shares in the company, valued at approximately $1,895,493.96. The trade was a 12.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 942,672 shares of company stock worth $64,058,781. Corporate insiders own 6.40% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a research report on Thursday, March 27th. Piper Sandler increased their price objective on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Robert W. Baird lifted their target price on shares of Soleno Therapeutics from $102.00 to $105.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Finally, Stifel Nicolaus raised their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, March 28th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $106.78.

Soleno Therapeutics Stock Down 1.3%

SLNO traded down $1.05 during trading on Friday, hitting $79.15. The company had a trading volume of 621,294 shares, compared to its average volume of 766,488. The company has a market capitalization of $3.99 billion, a PE ratio of -23.84 and a beta of -2.69. Soleno Therapeutics, Inc. has a one year low of $36.93 and a one year high of $81.54. The firm's 50-day moving average price is $73.24 and its 200 day moving average price is $57.77.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.19. Sell-side analysts forecast that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.